Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts, USA.
J Gerontol A Biol Sci Med Sci. 2024 Nov 1;79(11). doi: 10.1093/gerona/glae219.
Prescribing cholinesterase inhibitors (ChEIs) concurrently with beta-blockers might cause syncope that increases the risk of fall-related injuries (FRIs). This self-controlled case series study assesses the risk of FRIs associated with initiating ChEIs while receiving beta-blockers among Medicare fee-for-service-insured nursing home (NH) residents in the United States.
We identified individuals at their first dispensing of a beta-blocker between 2016 and 2019 after at least 45 days of long-stay NH residency. Individuals were followed from the first day of beta-blocker use until beta-blocker discontinuation, Medicare disenrollment, death, or study end. ChEI initiation was classified as the first 60 days of new ChEI dispensing after 45 days of no ChEI exposure. FRIs were assessed during beta-blocker use periods, and age-adjusted incidence rate ratios (IRR) for ChEI-initiation days versus other days were calculated using conditional Poisson regression models. Analyses were weighted for event-dependent observation periods due to the high risk of mortality after an FRI in this population. Subgroup analyses were conducted for several key time-fixed variables, including sex, age, ChEI type, ChEI dose, beta-blocker selectivity, and beta-blocker dose.
The FRI risk after ChEI initiation was not elevated among 837 residents who experienced an FRI while using beta-blockers (IRR=0.90 [95%CLs 0.71, 1.15]). Analyses of ChEI initiation in several subgroups yielded similar results.
There was no substantial difference in FRI risk when initiating ChEIs among older NH residents receiving beta-blocker therapy versus periods without ChEI initiation, suggesting that there is no clinically significant pharmacodynamic drug-drug interaction between beta-blockers and ChEIs.
同时开具胆碱酯酶抑制剂 (ChEIs) 和β受体阻滞剂可能导致晕厥,从而增加跌倒相关伤害 (FRIs) 的风险。本自我对照病例系列研究评估了在美国接受医疗保险按服务付费的养老院 (NH) 居民中,同时接受β受体阻滞剂和 ChEIs 治疗时,起始 ChEIs 与 FRIs 相关的风险。
我们在至少 45 天的长期 NH 居住后,在 2016 年至 2019 年期间,确定了每位首次开具β受体阻滞剂的个体。个体从使用β受体阻滞剂的第一天开始随访,直至β受体阻滞剂停药、退出医疗保险、死亡或研究结束。ChEI 起始被定义为在没有 ChEI 暴露的 45 天后,新的 ChEI 分配的前 60 天。在使用β受体阻滞剂期间评估 FRIs,并使用条件泊松回归模型计算 ChEI 起始日与其他日的年龄调整发生率比 (IRR)。由于该人群中 FRIs 后死亡率较高,因此对事件相关观察期进行了加权分析。进行了几项关键时间固定变量的亚组分析,包括性别、年龄、ChEI 类型、ChEI 剂量、β受体阻滞剂选择性和β受体阻滞剂剂量。
在 837 名使用β受体阻滞剂时经历 FRIs 的患者中,ChEI 起始后 FRIs 的风险并未升高(IRR=0.90 [95%CLs 0.71, 1.15])。对几个亚组中 ChEI 起始的分析得出了相似的结果。
在接受β受体阻滞剂治疗的老年 NH 居民中,与没有 ChEI 起始的时期相比,起始 ChEIs 时 FRIs 的风险没有显著差异,这表明β受体阻滞剂和 ChEIs 之间没有明显的药效学药物相互作用。